Clinical trials
Glomerulonephritis, IGA trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 5 |
| Completed | 3 |
| Recruiting | 3 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 2 |
| Calliditas Therapeutics AB | 2 |
| Novartis Pharmaceuticals | 2 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| Travere Therapeutics, Inc. | 2 |
| Alpine Immune Sciences Inc, A Subsidiary of Vertex | 1 |
| Biogen | 1 |
| Eledon Pharmaceuticals | 1 |
| Hoffmann-La Roche | 1 |
| Medical University of Warsaw | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glomerulonephritis, IGA | 16 |
| Proteinuria | 4 |
| Glomerulonephritis | 3 |
| Renal Insufficiency, Chronic | 3 |
| Glomerulosclerosis, Focal Segmental | 1 |
| IgA Vasculitis | 1 |
| Kidney Diseases | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Lupus Nephritis | 1 |
| Nephritis, Hereditary | 1 |
Trials
Showing 26 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.